Allergan recalls Refresh, FML, Blephamide eye drops

Article

Allergan recently issued a voluntary U.S. recall of its Refresh Lacri-Lube, Refresh P.M., FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment) 10%/0.2% due to customer complaints of small black particles at the time of use.

Dublin-Allergan recently issued a voluntary U.S. recall of its Refresh Lacri-Lube, Refresh P.M., FML (fluorometholone ophthalmic ointment) 0.1%, and Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment) 10%/0.2% due to customer complaints of small black particles at the time of use.

According to Allergan, the black particle is part of the cap and can be created by the action of unscrewing the cap from the aluminum tube and potentially introduced into the product.

The company says the reported adverse events include:

• Foreign body in the eye

• Eye irritation

• Ocular discomfort

• Product contamination

• Superficial eye injury

• Eye pain

• Eye swelling

• Blurred vision

Allergan is recalling specific lots and does not affect any other Refresh or Allergan products. To see a complete list of the recalled lot numbers, CLICK HERE. The lot number and expiration date can be found on the bottom flap of the carton with the safety seal and on the crimp seal of the product tube.

If a patient experiences eye pain, swelling, ocular discomfort or irritation after using any of the recalled products, Allergan says the patient should contact a healthcare provider.

For any questions regarding product returns, contact GENCO at 877-674-2087 from 7 a.m. to 5 p.m. CST. For questions regarding credit or reimbursements, contact Allergan at 1-800-811-4148 from 7 a.m. to 5 p.m. PST. 

Related: Keep your patients safe during the CDC's Contact Lens Health Week

Recent Videos
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
© 2024 MJH Life Sciences

All rights reserved.